Treatment for Ageing Patient with Lower Leg Ulcer

Chosen case study: Cam Dao, a 68 year old woman who is being visited at home by the local Community Care Services for treatment of a lower leg ulcer.



Part A:


Healthy/Active Ageing:

The World Health Organisation (WHO) (2019) describes healthy ageing as the course of action for preserving and improving functional ability that supports well-being in older age. It is further described by Hunt (2017) as the taking on of activities to minimise the risk of illness and disease which leads to an improvement in physical, mental and emotional health. Hunt (2017) also states that these activities lessen the decline of functionality and improve quality of life for the ageing population. Not only does healthy active ageing support well-being, it reduces the risk of falls (Queensland Health, 2015). Physical activity and keeping active, helps older adults to stay independent (Queensland Health, 2015). If an incident such as a fall does occur, being more physically fit will reduce the damage (Queensland Health, 2015).

Functional capability consists of the intrinsic capacity of a person, the environment pertinent to the person and the relationship between these two aspects (World Health Organisation, 2019). Intrinsic capacity is made up of the mental and physical capacities of a person including their motor skills, their cognitive ability and their ability to hear and see (World Health Organisation, 2019). Intrinsic capacity can be affected by ageing, disease and injury (World Health Organisation, 2019). The environments pertinent to a person would include their home, their community and the society in which they live (World Health Organisation, 2019). It also includes people and their relationships, mind-sets and principles, policies about health, and the systems of support (World Health, 2019). Living in an environment that supports intrinsic capacity is the answer to healthy ageing (World Health Organisation, 2019).


Successful Ageing

In reality, researches have not yet reached an agreed definition of successful ageing (Sachdev, 2014). It is of importance to note that despite this, according to Sachdev (2014), their research shows that when elderly people were asked if they had aged successfully, their responses centred around the quality of their lives rather than placing concentrating on disease. Sachdev (2014) discusses an influential paper that was released in 1987 by Rowe and Kahn, who at the time summarised successful/positive ageing into three components: “freedom from disease and disability, high cognitive and physical functioning, and social and productive engagement.” Though it is seen that a lack of disease isn’t what is deemed most important by elderly people, what is deemed essential is their ability to adapt to illness, and upholding optimism and a feeling of purpose (Sachdev, 2014). In many surveys about successful ageing, psychological traits including optimism and resilience are perceived to be of great significance (Sachdev, 2014). Those reaching ages considered late elderly are seen to be people with more positive attitudes who do not focus on negative aspects of life such as regret (Sachdev, 2014). These people also tend to be well involved with society and have a large, close circle of friends and family (Sachdev, 2014). In one significant survey conducted, 90% if participants had rated themselves as having aged successfully despite the fact that only 15% reported nil diseases and 38% reporting nil disabilities (Sachdev, 2014). Once again more stress was put on good mental capacity, however even more than mental capacity, the importance of actively engaging with life, the ability to adapt to illness and ongoing growth were highlighted (Sachdev, 2014).


Support and Health Promotion

To maximise Cam’s quality of life and improve her participation in society/social interactions, as a nurse in this situation there a number of approaches that could be undertaken. Since Cam is currently receiving community care from the Community Registered Nurse, the nurse could make sure that when she comes to visit she is taking advantage of the fact she lives with her husband under their daughter’s house. Having family in the home and involving them in Cam’s care would be a way to make sure that the family is aware of the treatment plan so they can all assist and support Cam. It would also be useful because as stated in the situation Cam’s English can be hard to understand so having her family there to translate would greatly assist in the situation. It would be helpful for the nurse to explain to Cam and her family that these ulcers are more common than she would think and that she doesn’t need to be embarrassed by them. The nurse could also try and dress the wound more discretely so that it is more easily covered by long pants if this would help Cam’s self-confidence. She should also try and encourage Cam and her family to go out together more as having family present can increase a person’s confidence. It is important that the nurse does not try and rush Cam into anything and continue to reassure her to take small steps in becoming more social once again. Informing her that reconnecting with friends or even just spending some more time outside could greatly improve her mood and would also be beneficial to her mentality moving forward. She could also recommend even taking small walks, as to not increase pain too much, around the neighbourhood as a first small step and this would not only be socially beneficial but also a way to incorporate some physical activity into her daily routine.



Part B:


Biographical Approach to Assessment and Care Planning

According to Brown Wilson (2013), the elements needed to deliver a person-centred care plan and assessment are acknowledging the perspective of the elder person, finding out what matters to them, taking into account the important details of their life and cultivating conversational strategies to further involve the person in the decision-making process. In Australia, community care policies called for consumer-directed care so using this approach is fitting for the situation (Progomet et al., 2017).

In order to carry out person-centred assessments for Cam, the community nurse should begin with addressing Cam with her preferred name, asking her if she would like her family present while discussing care plans, what she knows about her condition and what she wants to achieve from community care. As Cam’s English is not easily understood it would be highly likely that Cam would have her husband and daughter present to assist with translating. Brown Wilson (2013) suggests to take into consideration the important details of her life. By using this the community nurse could endeavour to ask Cam questions about her hobbies and things she likes to do. By finding out these key elements it would allow for the nurse to recommend activities to Cam that would encourage her to leave the house more often. Cam has previously expressed feeling embarrassment about her ulcer. The nurse should take the opportunity to inform Cam that these ulcers are common and that she didn’t need to be embarrassed about them. It’s important that Cam not have a negative feeling towards the ulcer as shown in a studies that negative emotional response can affect healing time (Walburn et al., 2017).

As stated in the situation, Cam’s wound has become infected with a moderate amount of exudate. A moist wound provides the most ideal environment for wound healing, but finding a balance between a moist and dry wound is key (Brown, 2019). If there is an excessive amount of exudate, the nurse should consider using a superabsorbent dressing, while also making sure to clearly explain the situation to Cam (Brown, 2019). With the current condition of the wound it is paramount that the nurse monitor it closely as community care guidelines promote early intervention to prevent the wound from worsening (Littleford, 2010).


Stereotypes and Ageist Attitudes

Hunt (2017) defines ageism as the act of “stereotyping and discriminating against people because they are old (p. 397). There are many assumptions about older people including that they all are hard of hearing and/or cognitively slow, which leads to some nurses and other health professionals engaging in inappropriate behaviour.

It is clear that there are ageist attitudes present within the nursing community. One study reported that 87.5% of a first-year nursing cohort had engaged in negative behaviours, including talking slowly and loudly, to an elderly person (Frost, Ranse & Grealish, 2015). This is quite concerning considering studies show that elderly people experiencing ageism are shown to have poorer mental health (Lyons et al., 2017).

As a nurse it would be important to make sure that even when talking to a family member in a situation where they were acting as a translator, eye-contact should be established with the patient as well, friendly expressions should be used and ensuring there is no overcompensation on volume or slower talking pace as if you had assumed they were slower cognitively. This is important as it is seen that positive human contact can make a different to the lives of the elderly (Wilson, 2011).



References:

  • Brown, A. (2019). Caring for chronic wounds in the community.

    Journal of Community Nursing

    ,

    33

    (4), 18-24,26,28. Retrieved from

    https://search-proquest-com.ezproxy.library.uq.edu.au/docview/2272758193?accountid=14723
  • Brown Wilson, C. (2013).

    Caring for Older People: A Shared Approach

    (pp. 69-82).  London, Sage Publications.
  • Frost, J., Ranse, K., & Grealish, L. (2015). Assessing ageist behavious in undergraduate nursing students using the Relating to Older People Evaluation (ROPE) survey.

    Australasian Journal on Ageing, 35

    (1), 58-61. doi:

    10.1111/ajag.12260
  • Hunt, S. (2017). Working with older people. In Crisp, J., Douglas, C., Rebeiro, G., & Waters, D. (Ed.) Potter and Perry’s Fundamentals of Nursing – Australian version, (5th ed). (pp. 393-421) Sydney: Elsevier
  • Littleford, A. (2010). Making a difference through intergrated community care for older people.

    Journal of Nursing and Healthcare of Chronic Illness, 2

    (3), 178-186. doi: 10.1111/j.1752-9824.2010.01061.x
  • Lyons, A., Alba, B., Heywood, W., Fileborn, B., Minichiello, V., Barrett, C., Hinchliff, S., Malta, S., & Dow, B. (2018) Experiences of ageism and the mental health of older adults.

    Aging & Mental Health,




    22

    (11), 1456-1464. doi:

    10.1080/13607863.2017.1364347
  • Prgomet, M., Douglas, H.E., Tariq, A., Georgiou, A., Armour, P., & Westbrook, J.I. (2017) The Work of Front Line Community Aged Care Staff and the Impact of a Changing Policy Landscape and Consumer-Directed Care,

    The British Journal of Social Work

    ,

    47

    (1), January 2017, 106–124. doi:

    10.1093/bjsw/bcw112
  • Queensland Health. (2015).

    Healthy active ageing: How to get active.

    Retrieved from


  • https://www.health.qld.gov.au/stayonyourfeet/for-seniors/keep-active

  • Sachdev, P. (2014).

    What is Successful Ageing?

    Retrieved from

    https://cheba.unsw.edu.au/blog/what-successful-ageing
  • Walburn, J., Weinman, J., Norton, S., Hankins, M., Dawe, K., Banjoko, B., & Vedhara, K. (2017). Stress, Illness Perceptions, Behaviours, and Healing in Venous Leg Ulcers.

    Psychosomatic Medicine

    ,

    79

    (5), 585-592. doi: 10.1097/PSY.0000000000000436
  • Wilson, A. (2011). Improving Life Satisfaction for the Elderly Living Independently in the Community: Care Recipients’ Perspective of Volunteers.

    Social Work in Health Care, 51

    (2), 125-139. doi: 10.1080/00981389.2011.602579
  • World Health Organisation. (2019).

    Ageing and life-course: What is Healthy Ageing?

    Retrieved from


    https://www.who.int/ageing/healthy-ageing/en/

Home Visit With Sallie Mae Fisher

Home Visit With Sallie Mae Fisher

REQUIREMENTS:

Essay Portion

1) Identified and prioritized at least four problems from the simulated home visit with Salle Mae.

2) Summarized each problem identified with evidence to substantiate findings (assessment data).

3) Identified and discussed at least four medical and/or nursing interventions to meet client needs.

4) Provides rational for interventions identified. Discussion of rationale includes support from outside resources (current evidence-based literature).

Scripted Dialogue Portion

1) Utilizes information learned from the home visit, health history, and discharge orders presented in the simulation to develop a patient dialog.

2) Dialog addresses physiological, psychosocial, educational, and spiritual needs of the client.

Format/Style

1) Essay Portion
Prepare this step of the assignment according to the APA guidelines found in the APA Style Guide, located in the Student Success Center. An abstract is not required.
Information is paraphrased and not copied/pasted from other sources, including dictionaries, textbooks, e-books, and electronic links.

Public Health Delivery In Mauritius

As the saying goes “health is wealth”, the provision of proper healthcare is extremely important as this implies well-being, happiness, and a good quality of life. A healthy population is essential for the growth and prosperity of a country. A nation’s health system should thus aim at providing quality healthcare to its population.

The Ministry of Health & Quality of Life, to whom an overall yearly budget of Rs 5 billion is allocated, provides public healthcare in Mauritius as a “welfare” service. (Source: Newsletter Ministry of Health & Quality of Life July 2009). As at the year ended 2008, health services were provided through 13 public hospitals including 5 specialised ones, 22 Area Health Centres and 108 Community Health Centres located throughout the country. (Source: Ministry of Health & Quality of Life).

Free healthcare provided by the Ministry of Health & Quality of Life has improved the health situation of the citizens of Mauritius. This is shown in table 1.2 below.

Table 1.2: Health Indicators in Mauritius for the years 1990 and 2008 (Source: Ministry of Health & Quality of Life)

The health indicators in Table 1.2 show favourable changes in the health situation of Mauritians in 2008 compared to 1990.

Apart from providing health services to the citizens of Mauritius through its hospitals and health centres, The Ministry of Health & Quality of Life being highly concerned about the well-being of the Mauritian population, tries to create awareness amongst them by carrying out several welfare activities. The latter include the launching of a Mobile Clinic which was done on 7 May 2009, public demonstration of physical activities such as yoga, aerobics, Tai Chi and physical exercise that are organised to encourage people to adopt a healthy lifestyle, tips given with regards to a healthy nutrition so as to fight obesity, organising empowerment programmes to sensitise the population on the adverse effects of tobacco and alcohol, talks on stress management and a National Cancer Control Programme has been developed to fight against cancer. (Source: Newsletter Ministry of Health & Quality of Life July 2009)

Furthermore, The Ministry of Health & Quality of Life aims at improving the quality of healthcare provided to the citizens of Mauritius. Recently, on 27 April 2009, it introduced the implementation of the ISO 9001: 2008 in health services so as to increase customer satisfaction and meet the needs of the Mauritian population. (Newsletter Ministry of Health & Quality of Life July 2009). The future plans of the Ministry include the setting up of Medical Schools where proper training will be given to healthcare providers and improving the hospitality and catering services provided in its hospitals. (Source: Newsletter Ministry of Health & Quality of Life March 2009)

From the above, it can be noted that The Ministry of Health & Quality of Life is highly concerned with the health of the citizens of Mauritius. However despite all the efforts of The Ministry of Health & Quality of Life, the Mauritian population does not seem to be fully satisfied with its healthcare services. Patients are increasingly filing medical malpractice cases which nowadays are repeatedly seen as being the headline of many newspapers. Media reporting has created an increased awareness of harm related to healthcare errors.

Additionally, despite the fact that industrialisation and economic growth during the last years have positively changed the lifestyle and the standard of living of the Mauritian population, the latter is highly exposed to diseases such as diabetes, hypertension, obesity, cancer, HIV/AIDS and so forth. Research has shown that 1 out of 5 Mauritians aged 30 and above has diabetes that is mostly caused due to obesity, unhealthy eating habits, lack of physical activity and alcohol abuse. (Source: Newsletter Ministry of Health & Quality of Life July 2009)

The HIV/AIDS status in Mauritius is quite high with 3792 cases registered from October 1987 to March 2009. This has resulted in 249 deaths as at March 2009. Prior to 2000, 20 to 30 new cases of HIV were being reported annually. However over the period of 2001 – 2005 the number had increased by almost twice annually: 55 in 2001, 98 in 2002, 225 in 2003, 525 in 2004 and 921 in 2005. The 538 new cases registered in 2008 showed that in spite of all the efforts of the Ministry of Health & Quality of Life, HIV in Mauritius is on a rising trend. (Source: Ministry of Health & Quality of Life: An analysis of Health Situation in Mauritius as at year ended 2008)

Furthermore each year more than 1400 new cases of cancer are registered in Mauritius. In 2008, 12% of all deaths were due to this disease. (Source: Newsletter Ministry of Health & Quality of Life July 2009)

Heart diseases and Diabetes mellitus were the first two main causes of mortality in 2008. Comparing the causes of death in 2008 with those of 1975:

Causes

1975

2008

All diseases related to the circulatory system including heart diseases

28.4%

35.0%

Diabetes Mellitus

2.7%

22.8%

Table 1.3: Causes of death in the years 1975 and 2008 (Source: Ministry of Health & Quality of Life: An analysis of Health Situation in Mauritius for the year ended 2008)

Table 1.3 shows a rapid increase in death due to heart diseases and diabetes mellitus over the last three decades. This can be explained by a change in the lifestyle and eating habits of the citizens of Mauritius which is making them become more prone to such non-communicable diseases.

Morbidity in Mauritius and the litigation/complaints concerning medical mal-practice therefore indicate that the Ministry of Health & Quality of Life is not meeting the needs of the Mauritian population.

The healthcare system in Mauritius is getting bigger and more complex as the expectations of the population are increasing. The citizens of Mauritius who are now better educated, have become highly demanding in terms of choice, access, quality of care and service. They furthermore feel that the system is deteriorating and becoming less responsive to their needs as the press only publicises the bad points. Such negative media comments definitely demoralise the health care providers.

The aim of this project is to investigate the problems faced by the public health care sector of Mauritius. This will be done through an empirical study at Flacq Hospital, one of the well-known general hospitals operated by the Ministry of Health & Quality of Life. Throughout this study, it is intended to assess the healthcare quality provided at Flacq Hospital and analyse the factors linked to service experience and patient satisfaction.

By evaluating patient experience important information can be obtained for identifying problems and taking appropriate measures for quality improvement in health-care facilities (Labarere and François, 1999; Batchelor et al., 1994). Improving the quality of service in hospitals will thus be beneficial to everybody namely patients, physicians, nursing staff, management and tax-payers. Such a “win-win” situation will be advantageous to the whole country.

Chapter two Final Draft

Develop a final draft of Chapter 2 where you clearly provide a well-developed introduction and other sections relevant to your topic. This should be your first complete draft of Chapter Two. Before submitting, you should carefully review Chapter 2 and check the following:

Topic : Applications of Business Intelligence in Financial Technology (FinTech). Detailed topic is attached in the document

  • Use Grammarly in Microsoft Word to review your assignment before submitting it. Grammarly may show areas that you do not think need to be changed. If so, you should use the “trash” feature in Grammarly to remove each area that you do not think needs to be addressed.
  • You have to write 60 pages.
  • You should have at least 60 to 100 references. Review all of your references. Are all references in APA format? Do all in-text citations have an associated reference in the reference list? Do you have references in the reference list that are not cited in the chapters?
  • Did you follow the UC APA dissertation template?

Note: You will need to continually review and update Chapter Two as you work on other areas of the dissertation. Chapters are not complete and final until approved by your committee and you successfully defend.

Comparison of Treatments for Type 2 Diabetes and Cardiovascular Disease

Does a GLP1 agonist, Liraglutide, or a SGLT inhibitor, Empagliflozin, have a lower risk of cardiovascular events and mortality in a type 2 diabetics with established atherosclerotic cardiovascular disease?


Abstract:

Practicing medicine is an art. Type 2 Diabetes Mellitus is a disease where clinicians exercise their artistic skills in choosing antihyperglycemic drugs to control patient’s blood sugars. How does a provider choose a 2

nd

line drug for a type 2 diabetic with uncontrolled blood sugars? The American Diabetes Association states patients with diabetes mellitus type 2 and established atherosclerotic cardiovascular disease, needs anti-hyperglycemic therapy starting with lifestyle management and Metformin and subsequently incorporate an agent proven to reduce major adverse cardiovascular events and mortality (currently empagliflozin and liraglutide). This paper discusses which is better, GLP1 agonist to SGLTi, for 2

nd

line agents in type 2 diabetics with established atherosclerotic cardiovascular disease. Based on separate research journals from New England Journal of Medicine, Empagliflozin and Liraglutide underwent research in recording cardiovascular outcomes and mortality in type 2 diabetes. In the empagliflozin and liraglutide study, both groups had significantly lower rates of death from cardiovascular causes, and death from any cause compared to placebo. However, there was no significant difference in rates of myocardial infarction or stroke for either drug compared to placebo. However, rates of hospitalizations for heart failure were nonsignificantly lower in the liraglutide group, and significantly lower in the empagliflozin group. Both drugs prove to significantly lower the risk of death for type 2 diabetic with established atherosclerotic cardiovascular disease. No clear definitive 2

nd

agent exists to combine with Metformin for dual therapy. A clinician must consider a 2nd agent’s efficacy of A1C reduction, route of administration, effect on weight, cardiovascular effects, cost, renal considerations, FDA BBW, risk of hypoglycemia, and patient wishes.


Introduction:

Practicing medicine is an art. Just as an artist studies, uses, and works with a variety of artistic mediums, so must a clinician know the array of mediums for managing and treating diseases. Clinicians know there is no perfect way to treat chronic human illnesses. It takes years for clinicians to master their craft of medicine. For Diabetes Mellitus type 2, a multitude of medicines exist for controlling blood sugar.  Physician Assistants must choose their pharmaceutical tools carefully, with patient wishes in mind, in how they’ll paint a treatment plan for their individual patients. Diabetes and its management is important to discuss because it poses a significant health burden to the nation. 30.0 million people or 9.4% of the US population lives with diabetes.

1

Approximately 1.5 million new cases of diabetes were diagnosed in 2015 in patients 18 years old or older.

1

The CDC predicts by 2050 the incidence of diabetes could scope one in three adults by 2050.

2,3

This is alarming because diabetes is currently the seventh leading cause of death.

2

Will it be the leading cause of death by 2050? Type 2 diabetes is a risk factor for cardiovascular disease, and it’s also the leading cause of death in diabetics.

4

It’s evident diabetics need protection against cardiovascular events, especially if they already have established cardiovascular disease. Usually Metformin is the first-line medication for type 2 diabetics. A plethora of add-on options could be considered, such as glucoagon-like-peptide-1 (GLP-1), sodium-glucose-cotransporter 2 (SGLT2) inhibitors, or dipeptidyl peptidase-4 (DPP4) inhibitors. The American Diabetes Association states patients with diabetes mellitus type 2 and established atherosclerotic cardiovascular disease, needs anti-hyperglycemic therapy starting with lifestyle management, Metformin, and then add-on an agent proven to reduce major adverse cardiovascular events and mortality (currently empagliflozin and liraglutide).

5

Physician Assistants need to know how these two drugs effect cardiovascular events and mortality, because they can help lower the risk of those events and mortality for diabetic patients. No clear drug is a definite second line agent to combine with metformin for dual therapy.

2

Physician Assistants have to consider factors like A1C reduction, risks of hypoglycemia, cardiovascular effects, cost, effect on weight, renal considerations, and route of administration when selecting a add-on agent..

2

The mechanism of action of glucoagon-like-peptide-1, liraglutide (VICTOZA) binds to GLP-1 receptors and stimulates insulin release, slows gastric emptying, and reduces postprandial glucagon

4

. Sodium-glucose-cotransporter 2 inhibitors, empagliflozin (JARDIANCE), block glucose reabsorption in proximal renal tubule’s, causing renal excretion of glucose and lowering blood glucose.4 This paper examines the risk of cardiovascular events and mortality in a type 2 diabetic with established atherosclerotic cardiovascular disease taking either GLP-1 or SGLT inhibitor in conjunction with metformin.


Methods:

In searching for information for antihyperglycemic agents and cardiovascular outcomes, I used The New England Journal of Medicine, Journal of the American Academy of Physician Assistants, and the American Diabetes Association website. Key words I used in searching included Sodium-glucose-cotransporter 2 inhibitors, glucoagon-like-peptide-1, major adverse cardiovascular events for SGLT2i and GLP1 agonists, second line agent for type two diabetic with established cardiovascular disease. A majority of information came from the original trial articles from The New England Journal of Medicine.  The EMPA-REG trial  observed 7020 patients over a 3.1 year period

7

. EMPA-REG was a randomized, double blinded, placebo-controlled trial. The effect of empagliflozin, 10mg or 25mg once daily, was assessed “compared to placebo on cardiovascular events in adults with type two diabetes at high cardiovascular” risk while receiving standards of care.

7

The primary outcome was the total number of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.

7

The secondary outcome was the primary outcome plus hospitalization for unstable angina.

7

The trial also analyzed changes from baseline in hemoglobin level, systolic and diastolic blood pressure, weight, cholesterol, waist circumference, and heart rate.

7

The trial continued until a primary outcome event had occurred in 691 patients.

7

Inclusion criteria included body mass index of less than 45, at least 18 year of age, GFR more than 30, A1C of at least 7 and no more than 9 and “had received no glucose lowering agents for at least 12 weeks before randomization, or had received glucose lowering therapy for at least 12 weeks before randomization and had A1C of at least 7 and no more than10”, and all had cardiovascular disease.

7

Follow up visits occurred  at week 2, month 3, every 12 weeks until end of trial and 30 days after the end of treatment.

7

The LEADER trial observed 9340 patients over a mean of 3.8 years. LEADER was randomized, double blinded placebo-controlled trial to “assess the long-term effects of liraglutide, 1.8mg, on cardiovascular outcomes and other clinically important events”.

8

The primary outcome was analyzed by time-to-event of the “first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stoke”.

8

Inclusion criteria included age greater than 50 years old with at least one cardiovascular condition (coronary artery disease, stoke, peripheral vascular disease, chronic kidney disease stage 3 or more, and chronic heart failure grade 2 or 3), or age greater than 60 with at least one cardiovascular risk factor,  (microalbuminuria, proteinuria, hypertension, left ventricular hypertrophy, ankle-brachial index less than 0.9, or left ventricle dysfunction).

8

Follow up visits were month 1,3,6,and every 6 months after.

8


Results

Table 1: Primary & Secondary Cardiovascular Outcomes in EMPA-REG trial



The EMPA-REG results were as follows: primary outcome occurred 10.5% in the empagliflozin group than in placebo 12.2%, which is significantly lower.

7

The secondary outcome occurred in 12.8% in the empagliflozin group and 14.3 in placebo.

7

Compared to placebo, empagliflozin had lower risk of death from any cause, cardiovascular cause, or hospitalization for heart failure.

7

According to Tat, Empagliflozin has 32% reduction in death from any cause, and 38% composite reduction in death from cardiovascular causes, and heart failure or cardiovascular hospitalizations compared to placebo.

2

Surprisingly there was no difference in incident of myocardial infarction or stroke between groups.

7

4.8% of patients on empagliflozin compared to 5.4% on placebo had myocardial infarctions, and 3.5% to 3.0% respectively had strokes.

7

A1C range improved 0.54 to 0.6 percent compared to placebo.

7

Cardiovascular risk factors such as reduction in weight, waist circumference, uric acid level, and blood pressure all decreased slightly, but a increase in both LDL and HDL cholesterol occurred.

7

Rate of genital infection increased in the empagliflozin group compared to placebo.

7

The number to treat to prevent one death is 39 in a three year period.

7

In the LEADER trial, primary outcome of 13.0% liraglutide to 14.9% placebo occurred.

8

4.7% to 6.0% respectively had cardiovascular related death, and 8.2% to 9.6% respectively was the rate of death by any cause.

8

Liraglutide had a 22% in relative risk reduction of cardiovascular death, and 15% relative rate of reduction of all-cause death.

9

There was no significant difference in groups for frequency of nonfatal myocardial infarction and nonfatal stroke.

8

The liraglutide group’s A1C improved by 0.4% on average, weight loss averaged 2.3kg, systolic blood pressure decreased by 1.2mm Hg, and diastolic increased by 0.6mm Hg.

8

The most common adverse effect was gastrointestinal events.

8

The black box warning for liraglutide is risk for thyroid C-Cell tumors.

2

The number to treat to prevent one primary outcome event in three years is 66, and 98 for death of any cause.

8

According to Busko, patients who received a SGLT2 inhibitor had 1% lower rate of death and a 0.8% lower rate of cardiovascular death than placebo.

10

Busko also states patients who received a GLP1 agonist had 0.6% lower risk of death and 0.5% lower risk of cardiovascular death compared to placebo.

10

Table 2: Primary & Secondary Outcomes in LEADER trial


Discussion:

There is no exact second line pharmaceutical agent for diabetics with established cardiovascular disease. The American College of Endocrinology and American Association of Clinical Endocrinologists states lifestyle modifications including medical assisted weight loss is first line, then monotherapy with metformin when initial A1C less than 7.5%.

2

The order of preference for alternative monotherapy are as follows: GLP-1 receptor agonist, SGLT2 inhibitor, DPP-4 inhibitor, thiazolidinedione, alfa-glucosidase inhibitor, and sulfonylurea.

2

If target A1C isn’t achieved in 3 months of monotherapy then a second agent is added.

2

Order of preference includes: GLP-1  receptor agonist, SGLT2 inhibitor, DPP-4 inhibitor, thiazolidinedione, basal insulin, and sulfonylurea as the sixth choice.

2

No head to head trial exists comparing cardiovascular events on Liraglutide or Empagliflozin. However, the results from the EMPA-REG and LEADER trials provide important statistics for diabetics with cardiovascular disease. Empagliflozin and Liraglutide both significantly lower the rate of cardiovascular death and all cause of death. The FDA has approved Liraglutide and Empagliflozin for the indication of reducing cardiac mortality in adults with type 2 diabetes and established cardiovascular disease.

4

Empagliflozin seems to have a better reduction of morality than compared to the Liraglutide. However, different patient populations can benefit from one drug compared to the other. For example, Empagliflozin is better for a diabetic with heart failure, and sustained kidney function better than stage 4. Liraglutide is better for patients with deteriorating kidney function, or who’d rather inject themselves than take a pill.  Empagliflozin has potential benefits for reducing risk of hospitalization for heart failure and nephropathy.

4

Liraglutide offers benefits to reduce nephropathy too.

4

This paper simply focused on two therapy agents while the approach to treating diabetic is multidimensional. Hemoglobin A1C, weight loss, blood pressure, administration route, cost, potential side effects, and patient preference are a few examples of the variables needing consideration to individualize treatment.  Even the American Diabetes Association states “aggressive management of cardiovascular risk factors like blood pressure, lipid therapy, antiplatelet treatment and smoking cessation” is likely to have greater benefits than strict glycemic control.

6

Empgliflozin improved A1C and blood pressure, and is cheaper compared to Liraglutide. Liraglutide improved weight loss better than empagliflozin and is FDA approved for weight loss

5

. Interestingly, neither drug reduced the rate for non-fatal myocardial infarction or non-fatal stroke. Further trials are needed to discover why the rate of non-fatal myocardial infects and stroke did not improve. More data needs to evaluate cardiovascular mortality and morbidity in patients with low cardiovascular risk. In the eyes of the consumer, taking these drugs won’t decrease the risk of them having the heart attack or stroke, it only decreases the chance of dying from a cardiovascular event. Due to the mechanism of action of SLGT2i, the hemodynamic changes to blood volume and sugar excretion may be a leading cause of the observed benefits.  Perhaps the GLP-1 mechanism slowing gastric emptying and reducing postprandial glucagon is why greater weight loss occurred. Medical clinicians need to build a patient-centered approach to guide the choice of pharmaceutical agents. Further research needs to be conducted to know if the findings from EMPA-REG and LEADER can translate to other drugs in their respective class of medications?  Can other GLP-1 agonists have similar cardiovascular protection since Liraglutide proved it’s benefit? Can all SGLT2 inhibitors reduce the rate of hospitalizations for heart failure patients? In contrast, can the adverse effects of each drug be slapped on all other drugs within the respective classes of drugs? If all SGLT2 inhibitors increase the risk of genital infections, and have similar adverse effect profiles, can one SGLT2 inhibitor black box warning be generalized to all SGLT2 inhibitors?  Further research needs to investigate the amputation rate and safety of Empagliflozin, and other drugs of the SGLT2 inhibitors.  These results are successful landmarks to a bright future of preventing mortality while applying standards of care. In conclusion, either one of these drugs should be second line for a type 2 diabetics with established cardiovascular disease. Patients and their physician assistant have the resources of information to make informed decisions

Bibliography:

  1. Center for Disease Control and Prevention. National Diabetes Statistics Report, 2017.

    www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf

    . Accessed September 29, 2018.
  2. Tat V, Forest C. The role of SGLT2 inhibitors in managing type 2 diabetes.JAAPA.2018; 131(6): 35-40.
  3. Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popil Health Metr. 2010; 8:29.
  4. Covino J, Hoffman J. What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes? JAAPA; 31 (3): 12-14.
  5. Riddle MC, Makris G, Blonde L, et al. American Diabetes Association. Standards of Medical Care in Diabetes -2018. Diabetes Care. 2018; 41:  51 – 100.
  6. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35 (6): 1364 – 1379.
  7. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular outcomes, and mortality in itype 2 diabetes. N Engl J Med 2015;373:2117-28.
  8. Marso SP, Faniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375 (4): 311-322
  9. Novo Nordisk. Victoza liraglutide injection. Prescribing information V10.1. 2017. 1-11.
  10. Busko, M. Two New Drug Classes Tied to Better Survival in Type 2 Diabetes – Medscape – Apr 18, 2018.

    https://www.medscape.com/viewarticle/895331?loading=”lazy” src=WNL_infoc_180819_MSCPEDIT_TEMP2&uac=282512MN&impID=1714694&faf=1#vp_2

Need four responses to discussion questions 300 words min with

In many projects, teams are tempted to immediately identify solutions for implementation. Explain why is important to follow a process for understanding the problem, and who should be involved in final solution prioritization.

Explain, in your own words, the relationship between a project network and a project plan. Can a project plan be created without a project network? Why or why not? Provide a specific example and evidence from the readings to support your response.

Share a source you will use in writing your resource scheduling methods analysis paper. Provide an APA citation for the source. Provide a brief summary of the source, an evaluation of the merits or reliability of the source, and your personal reaction to the contents of the source such as whether or not you learned anything new regarding project management.

***see attachment**

On the “Problem Solutions Matrix,” handout, the category “Customer Importance” received twice the weight of all other categories. Using what you learned from the Topic Materials, discuss the relative importance of this criterion.

1. Discuss whether you think this weighting was appropriate, and explain why.

2. Discuss whether there are additional criteria that should have had greater weight and explain why.

Transition to Adulthood with Downs Syndrome

While the transition from school into adulthood is daunting for any teenager, it is more complex for those with a learning disability such as Downs Syndrome. There is a lot of decisions to be made; where to live, where to work and meeting new people outside of school life for example. This means early planning is essential to make this transition easier.

During their time in school, Downs syndrome children have an Individualized Education Programme (IEP) which includes transition planning.

1

The main aim of this is to think of the future and the skills and aims required for when they become adults. Making a solid plan for the future with help from teachers and healthcare providers such as doctors can make life less stressful.

As the end of school life approaches, this can cause teenagers with Downs syndrome to have mood swings or not preform as well in school. This is due to school being more than a place to learn, it is a place where they can regularly socialise with a good support system eg) IEP. Leaving this structured environment can be hard to accept and get used to. However, the school or GP can provide additional help and support to overcome this.



Living Arrangements:

Depending on their individual needs, adults with Downs syndrome have a variety of options of where they would like to live. These include;

  • Living at home with family.
  • Supported Living – on their own with the correct support.
  • Residential Care – in a home with others with disabilities.

    2




Jobs and Higher Education:

More adults with Downs syndrome are going onto further education such as college and university, while others are getting jobs. For those that decide to go straight into the workplace, there is three main type of jobs they can look for with the option of Volunteering. These are:

  • Competitive – goals can be reached with limited job support.
  • Supported – the same as competitive only with long-term or ongoing support to be successful. This is the most common type of job.
  • Sheltered – a setting where people with disabilities can attend on a daily basis and carry out subcontract work eg) assembling packaged goods.
  • Volunteer – for those who want to gain additional job training.

    3




Relationships and Social Well – Being:

Quality of life is considered a crucial component to the well-being of patients with Downs syndrome.

4

The strength of quality care through stable social and psychological interactions has built a framework for a positive well-being for patients with Downs syndrome, improving their quality of life.

5

This means that although working is important, it is essential for people with Down syndrome to take part in sport, hobbies and other interests they may have.

People with Downs syndrome also like to date, form loving relationships and some even get married. However, they may need additional support when it comes to things like birth control and STD’s. Some couples may even consider starting a family although the fertility rate for men and woman with Downs syndrome tends to be lower. This doesn’t mean they can’t have children, but it does tend to make it more difficult. It is also worth noting that if one partner in a couple has Downs Syndrome, there is a 1 in 2 chance of their children having Downs syndrome too. There is also an increased risk of miscarriage and premature birth within women with Downs syndrome. In addition to this, becoming a new parent is hard for anyone, and even more so for people with Down syndrome, so extra help, support and specialist guidance will be usually be required in order to cope with the demands of a new baby.

6



Health Issues:

Adults with Down Syndrome are now living longer – the average life expectancy is now between 50 and 60 years old with some people even reaching their 70s. As they get older, people with Down syndrome are more likely to suffer from mental health issues, like depression. This can be triggered by a variety of reasons, most commonly loss, like the death of a parent. In other instances, there are medical reasons.

In comparison to the general population there is an increased risk with early ageing and age-related health problems at an earlier stage of life. This includes dementia, memory loss, and changes in personality that are similar traits of Alzheimer’s disease.



  • Depression

Depression is just as common in the general population in comparison to those with Down Syndrome and both are affected in exactly the same way. It is the most commonly diagnosed mental health issue for those with Down Syndrome. Depression is much more than feeling sad or low for a short while. Symptoms usually persist for at least two weeks, and often much longer. Dr Kerim Munir (Boston Children’s Hospital) has

written

that children and adults with Downs syndrome and symptoms of depression often lose the ability to enjoy many activities they used to love, they lose skills and they become very withdrawn. Depression may have appeared relatively quick or may have developed gradually over the course of many months.

7

When mental health doctors meet with a patient to provide a diagnosis and treatment plan, they rely on standard diagnostic criteria which has been developed by the American Psychiatric Association.

8

Many of these criteria are based on the patient being able to self- report subjective feelings eg) feelings of worthlessness. This means diagnosing depression in a person with Downs Syndrome is extremely complicated, due to limited verbal communication and conceptual thinking which affect the individual’s participation in the psychiatric interview.

9

In addition to this, diagnosis may be further complicated by medical conditions such as hypothyroidism, vitamin B12 deficiency and Alzheimer’s dementia, all of which have symptoms that can mimic depression.

10

Treatment for depression includes;

  • Counselling
  • Medication
  • Treatment of any underlying associated medical conditions
  • Encouraging exercise and getting involved in activities that help build self-esteem





  • Dementia

Chromosome 21 carries the APP gene, which produces a specific protein called Amyloid Precursor Protein (APP). An excess amount of this protein causes a buildup of protein clumps (beta-amyloid plaques) in the brain.

11

As someone with Down Syndrome has an extra copy of chromosome 21, by the age of 40 they will have these plaques, and as a result, there is increased problems with how the brain cells function and therefore an increased risk of dementia.

It is important to note that not everyone with Down Syndrome will develop Alzheimer’s. However, for those that do, the signs and symptoms usual start to show around 40 – 50 years old. The most common early signs are changes in overall function, personality and behaviour compared to the usual symptoms of memory loss and forgetfulness. Examples of these signs include;

  • Reduced interest in being sociable, conversing or expressing thoughts.
  • Decreased enthusiasm for usual activities.
  • Decline in ability to pay attention.
  • Sadness, fearfulness or anxiety.
  • Irritability, uncooperativeness or aggression.

    12

Diagnosis of dementia is difficult in a person with down syndrome due to the challenges associated with an intellectual learning disability. Diagnosis usually takes a long time and can only be confirmed after consideration of a number of factors, including; detailed history, performance on assessments over an extended period of time and exclusion of all other possible reasons for change.

13

Although there is no cure for Alzheimer’s dementia, drugs such as donepezil (an anti-cholinesterase inhibitors) have been shown to be effective in alleviating symptoms and slowing progression.

Other health issues adults with Down syndrome tend to face include:

To help someone with Down syndrome remain healthy as they grow older, it is vital ensure they get regular check-ups and stay on top of any medical issues they have.

14


  1. https://www.webmd.com/a-to-z-guides/tips-adults-down-syndrome#1

  2. https://www.downs-syndrome.org.uk/for-families-and-carers/supported-living-2/
  3. Employment and Volunteer Work

  4. Goodman MJ, Brixner DI. New therapies for treating Down syndrome require quality of life measurements. Am J Med Genet A. 2013 Apr;161A(4):639-41
  5. Felce D, Perry J. Quality of life: the scope of the term and its breadth of measurement. In: Brown RI, editor. Quality of life for people with disabilities: models, research and practice. Cheltenham (UK): Stanley Thornes; 1997. p. 56-71.

  6. https://www.nhs.uk/conditions/downs-syndrome/living-with/

  7. https://www.downs-syndrome.org.uk/for-families-and-carers/health-and-well-being/getting-older/alzheimers-disease/
  8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association, 1995.

  9. https://www.advocatehealth.com/assets/documents/subsites/luth/downsyndrome/mcguir.pdf
  10. Szymanski LS. Diagnosis of mental disorders in retarded persons. In Stark JA, Menolascino FJ, Albarelli MH, Grey VC (eds), Mental Retardation and Mental Health: Classification, Diagnosis, Treatment Services. New York: Springer Verlag, 1988.

  11. https://www.nia.nih.gov/health/alzheimers-disease-people-down-syndrome

  12. https://www.alz.org/alzheimers-dementia/what-is-dementia/types-of-dementia/down-syndrome

  13. https://www.downs-syndrome.org.uk/for-families-and-carers/health-and-well-being/getting-older/alzheimers-disease/

  14. https://www.webmd.com/a-to-z-guides/tips-adults-down-syndrome#3


Develop and evaluate new practice approaches based on nursing theories and theories from other disciplines (AACN, 2006, p. 9).

Develop and evaluate new practice approaches based on nursing theories and theories from other disciplines (AACN, 2006, p. 9).

 

Introduces the purpose of the reflection and addresses DNP Essentials (AACN, 2006) pertinent to scientific underpinnings for practice.
Include a self-assessment regarding learning that you believe represents your skills, knowledge, and integrative abilities to meet the pertinent DNP Essential and sub-competencies (AACN, 2006) as a result of active learning throughout this course. Be sure to use examples from selected readings, threaded discussions, and/or applications to support your assertions to address each of the following sub-competencies:
(a) Integrate nursing science with knowledge from ethics, the biophysical, psychosocial, analytical, and organizational sciences as the basis for the highest level of nursing practice.
(b) Use science-based theories and concepts to: determine the nature and significance of health and health care delivery phenomena; describe the actions and advanced strategies to enhance, alleviate, and ameliorate health and health care delivery phenomena as appropriate; and evaluate outcomes.
Develop and evaluate new practice approaches based on nursing theories and theories from other disciplines (AACN, 2006, p. 9).
An effective conclusion identifies the main ideas and major conclusions from the body of your essay. Minor details are left out. Summarize the benefits of the pertinent DNP Essential and sub-competencies (AACN, 2006) pertaining to scientific underpinnings for practice.

Look in this references pleases
Chism, L. A. (2016). The Doctor of Nursing Practice: A guidebook for role development and professional issues(3rd ed.). Burlington, MA: Jones & Bartlett Publishers.
– Chapter 4: The DNP: Expectations for Theory, Research, and Scholarship
Zaccagnini, M. E. & White, K. W. (2017). The Doctor of Nursing Practice essentials: A new model for advanced practice (3rd ed.). Burlington, MA: Jones & Bartlett Publishers.
– Chapter 3: Clinical Scholarship and Evidence-Based Practice
Chamberlain College of Nursing. (2017). NR-700 Week 7: Emerging Roles for the DNP Prepared Nurse. [Online lesson]. Downers Grove, Il: DeVry Education Group.Currently 1 writers are viewing this order

Advanced practice nurses often treat patients with vein and artery disorders such as chronic venous insufficiency (CVI) and deep venous thrombosis (DVT). While the symptoms of both disorders are noticeable, these symptoms are sometimes mistaken for signs of other conditions, making the disorders difficult to diagnose.

Advanced practice nurses often treat patients with vein and artery disorders such as chronic venous insufficiency (CVI) and deep venous thrombosis (DVT). While the symptoms of both disorders are noticeable, these symptoms are sometimes mistaken for signs of other conditions, making the disorders difficult to diagnose.

Nurses must examine all symptoms and rule out other potential disorders before diagnosing and prescribing treatment for patients. In this Assignment, you explore the epidemiology, pathophysiology, and clinical presentation of CVI and DVT.
To prepare:
Review the section “Diseases of the Veins” (pp. 585–587) in Chapter 23 of the Huether and McCance text. Identify the pathophysiology of chronic venous insufficiency and deep venous thrombosis. Consider the similarities and differences between these disorders.
Select a patient factor different from the one you selected in this week’s Discussion: genetics, gender, ethnicity, age, or behavior. Think about how the factor you selected might impact the pathophysiology of CVI and DVT. Reflect on how you would diagnose and prescribe treatment of these disorders for a patient based on the factor you selected.
Review the “Mind Maps—Dementia, Endocarditis, and Gastro-oesophageal Reflux Disease (GERD)” media in the Week 2 Learning Resources. Use the examples in the media as a guide to construct two mind maps—one for chronic venous insufficiency and one for venous thrombosis. Consider the epidemiology and clinical presentation of both chronic venous insufficiency and deep venous thrombosis.
To complete:
Write a 2- to 3-page paper that addresses the following:
Compare the pathophysiology of chronic venous insufficiency and deep venous thrombosis. Describe how venous thrombosis is different from arterial thrombosis.
Explain how the patient factor you selected might impact the pathophysiology of CVI and DVT. Describe how you would diagnose and prescribe treatment of these disorders for a patient based on the factor you selected.
Construct two mind maps—one for chronic venous insufficiency and one for deep venous thrombosis. Include the epidemiology, pathophysiology, and clinical presentation, as well as the diagnosis and treatment you explained in your paper.

DVT Risk Assessment Tool for Nurses Using Modified Delphi

Research article


DEVELOPMENT OF PATIENT’S DVT RISK ASSESSMENT TOOL FOR NURSES USING MODIFIED DELPHI TECHNIQUE.

Mr.Kapil Sharma

1

,Ms. Jaspreet Kaur Sodhi

2

, *Ms.Rupinder Kaur

3


ABSTRACT


Background

Deep vein thrombosis (DVT) is a very serious, potentially fatal, and very preventable medical condition. It is important for all patients admitted to the hospital to be screened for the risk of developing a DVT. This could be easily accomplished by performing a risk factor assessment-screening tool on all patients. It is also important to educate the medical and nursing staff on the fact that all patients are at risk for developing DVT, not just surgical patients who are often believed to be at the highest risk of DVT. The implementation of the risk factor assessment could potentially save lives and reduce the hospital costs of treating and managing the complications of DVT and venous thromboembolic disease. The implementation of a risk factor assessment tool could potentially aid in the recognition and appropriate prophylaxis of those patients who are at extremely high risk for DVT. Without appropriate recognition of the risk for DVT, patients may be placed at risk for DVT and the potentially fatal and/or debilitating complications associated with the development of DVT.1


Aim

The aim of the study is to develop Patient’s DVT Risk Assessment Tool for Staff Nurses.


Objectives

  1. To select and pool the items to develop Patient’s DVT Risk Assessment Tool for Staff Nurses.
  2. To obtain consensus of Panelists for the development of Patient’s DVT Risk Assessment Tool for Staff Nurses.
  3. To organize valid items in a structured format for the development of Patient’s DVT Risk Assessment Tool for Staff Nurses.


Methods

Using instrument development design for Patient’s DVT Risk Assessment Tool for Staff Nurses. 66 Items were generated from evidence and qualitative data. Face and content validity were established through experts by 3 modified Delphi round. Content validity was computed. The content validity index (CVI) was calculated for each item i.e CVI-i, content validity index for experts i.e CVI-e and general content validity index for the tool i.e CVI-total. Item level CVI (CVI-i) is calculated by number of experts agreeing on the value of relevance of each item (value between 3 and 4) divided by total number of experts, expert level CVI (CVI-e) is calculated by number of items scored between 3 and 4 by an expert divided by total number of items and general CVI (CVI-total) is calculated by sum of all experts individual CVI divided by number of experts. Based on expert panel, CVI-i lower than 0.6 were deleted, (CVI-e) is 0.8,and CVI-total) 0.89.


Results

Patient’s DVT Risk Assessment Tool for Staff Nurses had face and content validity. The content validity index was 0.89.


Conclusion

The study concluded that assessment of DVT risk is essential in hospitalized patients.The identification of DVT risk at its earliest stage can help to decrease the morbidity and

mortality rate in hospitalized patients.The Patient’s DVT Risk Assessment Tool will be helpful to identify risk of DVT at its earliest stage so that preventive measures can be taken.


Keywords

Deep Vein Thrombosis,Patient’s DVT Risk Assessment Tool.Modified Delphi Technique,Content Validity Index


INTRODUCTION

“An ounce of prevention is cheap, the pound of cure costly”


(A.

Taylor, B.J. Whiting)

In India, the incidence of deep vein thrombosis (DVT) is not well highlighted and literature survey shows scanty works in this field. Most of the literature available in India is from the orthopaedic departments, overall incidence of DVT in general population is largely unknown. Most of the DVTs are idiopathic and occur in less than 45 years age group. Irrespective of the etiology, LMWH and Warfarins are efficient, safety is well demonstrated, and domiciliary treatment is advisable with surveillance. Idiopathic DVTs require long term follow up to watch for recurrent thrombosis.

2

Each year, deep vein thrombosis (DVT) occurs in 1 of every 1,000 Americans, hospitalizes nearly 600,000 for DVT-related complications, and kills up to 300,000. It is possibly the most common preventable cause of hospital deaths in the United States. Occupations in transportation, air travel, con­fined spaces, and sedentary office positions pose risks for DVT. The risk of DVT increases with factors such as obesity, cancer, pregnancy, estrogen-containing medications, major surgery, and hospitalizations. , With an understanding of DVT, occupational health nurses are well positioned to promote DVT awareness and reduce the risk of complica­tions for employees diagnosed with DVT.

3

Deep vein thrombosis [DVT] is one of the most dreaded complications in post-operative patients as it is associated with considerable morbidity and mortality. Majority of patients with postoperative DVT are asymptomatic. The pulmonary embolism, which is seen in 10% of the cases with proximal DVT, may be fatal. Therefore it becomes

imperative to prevent DVT rather than to diagnose and treat. Only one randomized trial has been reported from India to assess the effectiveness of low molecular weight heparin in preventing post-operative DVT.

4


METHODOLOGY

It is a methodological study to develop Patient’s DVT Risk Assessment Tool. The tool was validated by 10 multidisciplinary health care professionals. The study was conducted in 3 Modified Delphi rounds.The validity of tool was determined by content validity index (CVI). The data was collected via e-mail.The tool was developed under three phases and under each phase some steps were taken.


PHASE 1- Preliminary preparation

During this phase the investigator developed the preliminary Patient’s DVT Risk Assessment Tool for which the following steps were taken:


Step-1

: Review of Literature- An extensive review of literature was carried out from books, journals and through internet. Literature was searched which represent Patient’s DVT Risk Assessment Tool from all aspects. Various tool were searched. Literature related to tool construction and standardization was also reviewed.


Step-2:

Items selection and pooling- Different tools were analyzed and related items such as risk factors were selected from the content and items were pooled together.


Step-3:

Preparation of first draft- Selected items were seemed to represent Patient’s DVT Risk Assessment Tool to generate first draft of the tool.


PHASE 2- Validation of first draft and subsequent drafts


Step-1:

Selection of panel- There were 10 experts in all Delphi rounds. The Delphi panel was consisted of multidisciplinary health care professionals (nurses, doctors, and administrator). The sample of the panelist were heterogeneous to ensure the entire spectrum of opinion to be determined. The written consent was taken from the selected experts to participate in the study. The first draft of tool was circulated among 10 experts from above stated field.


Step-2:

Delphi Rounds: The modified Delphi technique was used to validate the draft. (The Delphi is an interactive process designed to combine expert’s opinion into group consensus.

According to this technique the response of each panelist remains anonymous that there are equal chances of each panelist to present the ideas unbiased by the identity of other panelist. There are subsequent Delphi rounds until a definitive level of consensus is recorded). All the panelist were requested to give their valuable suggestion pertaining to the content,

accuracy of information, the item order i.e organization and sequence of the items and working of the items. The suggestions given by panelist was incorporated to generate the second draft of tool.


Step-3:

Modification: as per the experts opinion:The modification in the tool was made.


PHASE 3- Assessing reliability and content validity of tool:

Draft prepared after third Delphi round.


Validity of Tool:

It was done by expert’s opinion. The tool was circulated to 10 experts of various specialties . The experts were asked to rate the items in terms of relevance to the Patient’s DVT Risk Assessment Tool. A 4 point likert scale (1 not relevant, 2 somewhat relevant, 3 relevant, very relevant). The content validity index (CVI) was calculated for each item i.e CVI-i, content validity index for experts i.e CVI-e and general content validity index for the tool i.e CVI-total. Item level CVI (CVI-i) is calculated by number of experts agreeing on the value of relevance of each item (value between 3 and 4) divided by total number of experts, expert level CVI (CVI-e) is calculated by number of items scored between 3 and 4 by an expert divided by total number of items and general CVI (CVI-total) is calculated by sum of all experts individual CVI divided by number of experts. Based on expert panel, CVI-i lower than 0.6 were deleted, (CVI-e) is 0.8, and CVI-total) 0.89.


Instrument development:

The content validity assessment process described by Waltz and Bausell (1981) and Lynn (1986) was used. 66 items were generated and were carefully investigated for clarity, grammar, and construction. A likert scale was chosen as scale type. Each item was rated on 4 point likert scale (1 not relevant, 2 somewhat relevant, 3 relevant, very relevant) with significant agreement (10 experts rating item a 4 or 3) needed for it to be retained. The experts were asked also to evaluate the set of items to determine if any content area was missing.


REFERENCES

1.

Race TK

,

Collier PE

. The hidden risk of deep vein thrombosis – the need for risk factor assessment: case reviews. Critical Care Nursing Quarterly [serial on the Internet]. 2007, July;30(3): 245-254.

2.

L Chinglensana

,

Santhosh Rudrappa

,

K Anupama

,

T Gojendra

,

Kala K Singh

,

Sudhir T Chandra

. Clinical profile and management of deep vein thrombosis of lower limb. Journal Of Medical Society.2013;27(1):10-14

3. Emanuele, P,. Deep Vein Thrombosis, AAOHN Journal 2008; 56(9):389-392.

4.

Anandan Murugesan

,

Dina N. Srivastava

,

Uma K. Ballehaninna

,

Sunil Chumber

,

Anita Dhar

,

Mahesh C. Misra

,

Rajinder Parshad

,

V. Seenu

,

Anurag Srivastava

,and

Narmada P. Gupta

. Detection and Prevention of Post-Operative Deep Vein Thrombosis [DVT] Using Nadroparin Among Patients Undergoing Major Abdominal Operations in India; a Randomised Controlled Trial. Indian J Surg. 2010 August; 72(4): 312–317